Furthermore, abnormal DR6 expression has been suggested as a diagnostic or prognostic biomarker for some cancers, such as glioma, sarcoma, and ovarian cancer (Ren et al. 2022). This evidence concerns the gene TNFRSF21 and ovarian cancer.